Zobrazeno 1 - 10
of 385
pro vyhledávání: '"Drug–Drug Interaction (DDI)"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveThis study aims to examine the unresolved drug-drug interactions of warfarin using real-world data.MethodsElectronic medical records from a hospital in Shanghai, China, were used to summarize drug-related problems (DRPs) among inpatients tak
Externí odkaz:
https://doaj.org/article/d11c8b0d4061468fb365623fc4d74156
Publikováno v:
Pharmaceutics, Vol 16, Iss 8, p 992 (2024)
Of the 450 cell membrane transporters responsible for shuttling substrates, nutrients, hormones, neurotransmitters, antioxidants, and signaling molecules, approximately nine are associated with clinically relevant drug–drug interactions (DDIs) due
Externí odkaz:
https://doaj.org/article/e673aa70b048492ea899e5b6e6643a58
Autor:
Xuefen Yin, Brian Cicali, Leyanis Rodriguez-Vera, Viera Lukacova, Rodrigo Cristofoletti, Stephan Schmidt
Publikováno v:
Pharmaceutics, Vol 16, Iss 6, p 737 (2024)
Carbamazepine (CBZ) is commonly prescribed for epilepsy and frequently used in polypharmacy. However, concerns arise regarding its ability to induce the metabolism of other drugs, including itself, potentially leading to the undertreatment of co-admi
Externí odkaz:
https://doaj.org/article/aa09ac29b3c6427e9fd2dfccb09dc310
Autor:
Resia Perwirani, Ika Puspitasari
Publikováno v:
Jurnal Manajemen dan Pelayanan Farmasi, Vol 12, Iss 4, Pp 198-207 (2023)
Not all drugs side-effect that occur can be avoided, but those caused by drug-drug interactions (DDI) are among the most likely to be prevented and managed due to their predictability. The increasing number of drugs co-prescribed, affects the potenti
Externí odkaz:
https://doaj.org/article/4e3841dd82ae41339db7be7188f64ea1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Dallas J. Smith, Huichang Bi, Josias Hamman, Xiaochao Ma, Constance Mitchell, Kumbukani Nyirenda, Tsitsi Monera-Penduka, Hellen Oketch-Rabah, Mary F. Paine, Syril Pettit, Wihan Pheiffer, Richard B. Van Breemen, Michelle Embry
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The COVID-19 pandemic sparked the development of novel anti-viral drugs that have shown to be effective in reducing both fatality and hospitalization rates in patients with elevated risk for COVID-19 related morbidity or mortality. Currently, nirmatr
Externí odkaz:
https://doaj.org/article/2c10c122871b4cbd8f121c7cf1e9f346
Autor:
Hayato Akimoto, Takashi Hayakawa, Takuya Nagashima, Kimino Minagawa, Yasuo Takahashi, Satoshi Asai
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Acute kidney injury (AKI), with an increase in serum creatinine, is a common adverse drug event. Although various clinical studies have investigated whether a combination of two nephrotoxic drugs has an increased risk of AKI using traditi
Externí odkaz:
https://doaj.org/article/ba5e3c8f3fc846c6b9cd4035eb407407
Autor:
Vanessa Zhu, Jürgen Burhenne, Johanna Weiss, Mathias Haag, Ute Hofmann, Matthias Schwab, Stephan Urban, Gerd Mikus, David Czock, Walter E. Haefeli, Antje Blank
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transpor
Externí odkaz:
https://doaj.org/article/9dadd7a5884e42199ebe15eb6e6fa246